Medtronic's insulin pump recall gets FDA's highest-risk label

July 15, 2013 by Arezu Sarvestani

U.S. healthcare regulators put their highest-risk Class I label on Medtronic's Paradigm insulin infusion pump recall.

Medtronic logo

The FDA put its highest-risk label, Class I, on a recall of Medtronic's (NYSE:MDT) Paradigm insulin infusion pumps, which the medtech giant had warned about earlier this year.

Medtronic Canada said last month that it received 2 reports on its Paradigm and Polyfin infusion devices, concerning the over- and under-delivery of insulin therapy.

Medtronic informed patients, healthcare providers and pharmacies in Canada of the potential problem, to explain how to avoid it, according to the Brampton Guardian.

Sign up to get our free newsletters delivered right to your inbox.

In an update issued July 12, the FDA said that the Paradigm pumps were recalled "because of a potential safety issue that can occur if insulin or other fluids come in contact with the inside of the tubing connector."

"If this occurs it can temporarily block the vents that allow the pump to properly prime," according to the FDA notice. "This can result in too much or too little insulin being delivered resulting in hypoglycemia or hyperglycemia which can be severe and lead to serious illness."